Small molecule · Inhibitor of KRAS · developed by Erasca
ERAS-4001 is an orally bioavailable pan-KRAS inhibitor that binds KRAS wild-type and various KRAS mutant forms, inhibiting KRAS-dependent signaling. It is being studied in metastatic solid tumors, alone and in combination with pembrolizumab or panitumumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07021898 | Phase 1 | Metastatic Solid Tumors | Recruiting | ERAS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Solid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the ERAS page.
See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ERAS catalysts and pipeline →